LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Rating of “Moderate Buy” by Brokerages

LifeMD, Inc. (NASDAQ:LFMD) has been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $7.5714.

Several research firms recently weighed in on LFMD. KeyCorp set a $5.00 target price on shares of LifeMD and gave the company an “overweight” rating in a report on Friday, August 7th. HC Wainwright lowered their price target on LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a research note on Monday. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Lake Street Capital set a $5.00 target price on LifeMD in a research note on Thursday, August 6th.

LifeMD Price Performance

Shares of LFMD stock opened at $3.28 on Friday. The firm has a market cap of $158.10 million, a PE ratio of -65.59 and a beta of 2.02. The company has a 50-day moving average of $4.13 and a two-hundred day moving average of $3.97. LifeMD has a 1-year low of $2.56 and a 1-year high of $7.32.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. The company had revenue of $47.28 million for the quarter, compared to analyst estimates of $49.16 million. Sell-side analysts anticipate that LifeMD will post -0.48 EPS for the current fiscal year.

Institutional Trading of LifeMD

A number of institutional investors and hedge funds have recently bought and sold shares of LFMD. Walleye Capital LLC acquired a new stake in LifeMD during the 2nd quarter worth approximately $1,338,000. Russell Investments Group Ltd. boosted its position in LifeMD by 5,801.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company’s stock valued at $1,300,000 after buying an additional 309,436 shares during the period. Whetstone Capital Advisors LLC grew its stake in shares of LifeMD by 89.6% in the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock worth $2,397,000 after acquiring an additional 332,269 shares in the last quarter. Prescott Group Capital Management L.L.C. acquired a new position in shares of LifeMD in the fourth quarter worth $2,344,000. Finally, MYDA Advisors LLC purchased a new stake in shares of LifeMD during the fourth quarter worth $512,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.